medicalxpress - The encouraging results of the world's first trial of a fridge-free tetanus-diphtheria vaccine could improve access worldwide to crucial treatments while reducing carbon emissions. Fridge-free vaccines have the potential to transform vaccine delivery by r…
AI Summary: Early studies of fridge‑free vaccine formulations, including a tetanus‑diphtheria candidate, indicate stability without cold storage, promising to reduce discarded doses and simplify distribution in low‑resource settings. If these results hold up, the change could shrink logistical headaches, boost global immunization reach and finally make the vaccine refrigerator’s light a little less terrifying.
Favipiravir shows promise in Lassa fever Phase 2 trial / 3 months
Engineered 15‑strain biotherapeutic matches donor FMT for C. difficile / 2 months
One hepatitis B drug shows early functional cures in trial / 3 months
WHO approves first malaria treatment for infants; Novartis drug prequalified / 4 months
Study finds MenB vaccine does not prevent gonorrhea in men / 7 wks
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 3 months
First‑in‑human CRISPR/Cas12a sickle cell therapy treated; gene editing shows promise / 4 months
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.